Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 7:14 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1105–1128 of 7,052 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo- matched Clear all

Conditions: Acute Ischemic Stroke (AIS)
Interventions: Placebo, scp776 (1.9 mg/kg), scp776 (3.8 mg/kg), scp776 (4.8 mg/kg), scp776 (all dose levels); Drug
Lead sponsor: Silver Creek Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 22
States / cities: Scottsdale, Arizona • Tucson, Arizona • Hartford, Connecticut + 18 more

Conditions: Alcohol Drinking, Control
Interventions: N-Acetylcysteine, Placebo Oral Capsule; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 15 Years to 19 Years
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Muscular Atrophy, Spinal
Interventions: Hydroxyurea, Placebo to match hydroxyurea; Drug
Lead sponsor: Stanford University; Other
Eligibility: Up to 2 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2012
U.S. locations: 1
States / cities: Stanford, California

Conditions: Multiple Myeloma
Interventions: Allogeneic HSCT, Fludarabine, Melphalan, Bortezomib, Ixazomib, Placebo; Procedure · Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 15
States / cities: Birmingham, Alabama • Duarte, California • Tampa, Florida + 11 more

Conditions: Narcolepsy Type 2
Interventions: TAK-360, Placebo; Drug · Other
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 31
States / cities: Auburn, Alabama • Chandler, Arizona • Chula Vista, California + 26 more

Conditions: Plaque Psoriasis
Interventions: AGN-242428, Placebo; Drug
Lead sponsor: Vitae Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 15
States / cities: Birmingham, Alabama • Tucson, Arizona • Fort Smith, Arkansas + 12 more

Conditions: Alzheimer's Disease
Interventions: MK-1942, Donepezil, Placebo; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 4
States / cities: Rogers, Arkansas • Hallandale, Florida • Decatur, Georgia + 1 more

Conditions: Cardiovascular Diseases, Vascular Dilation
Interventions: Ifetroban Sodium, Placebo; Drug
Lead sponsor: Jeffrey Rade; Other
Eligibility: 18 Years to 80 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Autism Spectrum Disorder, Autism
Interventions: Minocycline, Placebos; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 12 Years to 22 Years
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 3
States / cities: Columbia, Missouri • Cincinnati, Ohio • Pittsburgh, Pennsylvania

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Ivacaftor, Placebo; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 40 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Muscular Dystrophy, Duchenne
Interventions: Edasalonexent, Placebo; Drug
Lead sponsor: Catabasis Pharmaceuticals; Industry
Eligibility: 4 Years to 7 Years · Male only
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 5
States / cities: Los Angeles, California • Gainesville, Florida • Orlando, Florida + 2 more

Conditions: Schizophrenia
Interventions: Iloperidone, Placebo; Drug
Lead sponsor: Vanda Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 635 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 28
States / cities: Anaheim, California • Bellflower, California • Costa Mesa, California + 22 more

Conditions: Migraine
Interventions: 0.5% bupivicaine and 2% lidocaine, Saline placebo; Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: HIV-associated Enteropathy
Interventions: Serum-derived bovine immunoglobulin protein isolate (SBI), Placebo; Other
Lead sponsor: Entera Health, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 10
States / cities: Los Angeles, California • Sacramento, California • San Francisco, California + 7 more

Conditions: Healthy Volunteers
Interventions: GSBR-1290 (Capsule/Tablet), GSBR-1290, Placebo, Placebo (Capsule/Tablet); Drug
Lead sponsor: Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 3
States / cities: Miami, Florida • Baltimore, Maryland

Conditions: Lack of Satiety, Excess Intake of Macronutrients, Appetite Disorders
Interventions: Whey, Whey-CMP, Control, CMP, MPI, CPI; Other
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2015
U.S. locations: 1
States / cities: Davis, California

Conditions: Dry Eye Disease
Interventions: Lifitegrast, Placebo; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years and older
Enrollment: 711 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 41
States / cities: Birmingham, Alabama • Chandler, Arizona • Artesia, California + 33 more

Conditions: Depression
Interventions: 2:1 EPA/DHA, High EPA, Placebo; Drug · Other
Lead sponsor: Wei Jiang; Other
Eligibility: 21 Years and older
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 3
States / cities: Chapel Hill, North Carolina • Durham, North Carolina • Philadelphia, Pennsylvania

Conditions: Obesity, Weight Gain, Food Preferences
Interventions: Broth; Other
Lead sponsor: USDA, Western Human Nutrition Research Center; Federal
Eligibility: 19 Years to 50 Years · Female only
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Davis, California

Conditions: Healthy, Hepatitis C
Interventions: BMS-986094/INX-08189, Placebo matching BMS-986094/INX-08189; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 113 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 4
States / cities: Los Angeles, California • Saint Paul, Minnesota • Knoxville, Tennessee + 1 more

Conditions: Subjects With Hyperlipidemia, Dyslipidemia and HIV Infection
Interventions: Evolocumab, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 467 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 20
States / cities: Los Angeles, California • Hartford, Connecticut • Washington D.C., District of Columbia + 15 more

Conditions: Chronic Heart Failure
Interventions: JTT-861 Capsules, Placebo Capsules; Drug
Lead sponsor: Shionogi Inc.; Industry
Eligibility: 30 Years to 85 Years
Enrollment: 314 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 20
States / cities: Phoenix, Arizona • Crystal River, Florida • Hialeah, Florida + 16 more

Conditions: Obesity, Overweight
Interventions: Tirzepatide, Placebo; Drug · Other
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 579 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 45
States / cities: Huntington Park, California • Los Angeles, California • Montclair, California + 42 more

Conditions: Obesity &Amp; Overweight
Interventions: Freeze-dried grape powder, Placebo powder; Other
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 18 Years to 60 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Columbia, Missouri

Search by objective public record fields.

Study of the Safety and Neuroprotective Capacity of Scp776 in Acute Ischemic Stroke

Neuroscience-Informed Treatment Development for Adolescent Alcohol Use

A Pilot Therapeutic Trial Using Hydroxyurea in Type I Spinal Muscular Atrophy Patients

Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302)

A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2)

AGN-242428 in the Treatment of Plaque Psoriasis

MK-1942/Donepezil Interactions in Participants With Alzheimer's Disease (MK-1942-005)

Thromboxane Receptor Antagonist to Improve Endothelial Function

A Proof-of-Concept Study of Minocycline in Autism

TOPIC Trial for COPD

Phase 1/2 Study in Boys With Duchenne Muscular Dystrophy

Relapse Prevention Study in Patients With Schizophrenia

Research Study of Greater Occipital Nerve Block As A Treatment For Prolonged Migraine Attacks

Impact of SBI, a Medical Food, on Nutritional Status in Patients With HIV-associated Enteropathy

A Study of Multiple-ascending Doses of GSBR-1290 in Healthy Overweight/Obese Participants

Casinomacropeptide and Satiety

A Study to Evaluate Efficacy and Safety of Lifitegrast in Subjects With Dry Eye (OPUS-3)

Omega 3 for Treatment of Depression in Patients With Heart Failure

Effects of Monosodium Glutamate on Energy Balance and Eating Behavior

A Follow-up Evaluation for Safety in Subjects Who Participated in a Phase 1 Study With BMS-986094 (INX-08189)

Safety, Tolerability and Efficacy on Low Density Lipoprotein Cholesterol (LDL-C) of Evolocumab in Participants With Human Immunodeficiency Virus (HIV) and Hyperlipidemia/Mixed Dyslipidemia

Evaluate Efficacy, Safety and Tolerability of JTT-861 in Subjects With Heart Failure With Reduced Ejection Fraction

A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program

Effects of Grape Consumption on the Immune-Gut Axis in Obesity